See more : AMCI Acquisition Corp. II (AMCI) Income Statement Analysis – Financial Results
Complete financial analysis of Inhibitor Therapeutics, Inc. (INTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inhibitor Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wuhan General Group (China), Inc. (WUHN) Income Statement Analysis – Financial Results
- RDC Semiconductor Co., Ltd. (3228.TWO) Income Statement Analysis – Financial Results
- ERI Holdings Co., Ltd. (6083.T) Income Statement Analysis – Financial Results
- Star Phoenix Group Ltd (RGRLF) Income Statement Analysis – Financial Results
- SHAMROCK INDUSTRIAL CO.LTD. (SHAMROIN.BO) Income Statement Analysis – Financial Results
Inhibitor Therapeutics, Inc. (INTI)
About Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -26.49K | 0.00 | 0.00 | 0.00 | 610.28K | 3.27M | 9.44M | 12.42M | 6.53M | 7.80M | 5.75M | 5.10M | 4.43M | 4.79M | 4.37M | 2.57M | 1.60M | 1.80M | 1.00M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 560.67K | 0.00 | 0.00 | 2.26M | 7.22M | 10.63M | 5.44M | 5.49M | 3.77M | 3.53M | 3.29M | 3.87M | 2.05M | 1.13M | 800.00K | 500.00K | 100.00K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -26.49K | 0.00 | -560.67K | 0.00 | 610.28K | 1.01M | 2.21M | 1.80M | 1.09M | 2.31M | 1.98M | 1.58M | 1.14M | 916.18K | 2.32M | 1.44M | 800.00K | 1.30M | 900.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 30.89% | 23.44% | 14.47% | 16.74% | 29.59% | 34.45% | 30.87% | 25.81% | 19.14% | 53.07% | 56.01% | 50.00% | 72.22% | 90.00% |
| Research & Development | 1.38M | 6.15K | 4.91K | 185.29K | 1.21M | 2.63M | 2.23M | 2.64M | 1.68M | 2.43M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.31K | 14.35K | 149.54K | 379.75K | 500.00K | 600.00K | 300.00K |
| General & Administrative | 2.02M | 651.78K | 320.49K | 873.70K | 1.54M | 1.93M | 2.89M | 4.38M | 2.27M | 1.51M | 817.32K | 560.67K | 0.00 | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.02M | 651.78K | 320.49K | 873.70K | 1.54M | 1.93M | 2.89M | 4.38M | 2.27M | 1.51M | 817.32K | 560.67K | 982.10K | 1.03M | 3.08M | 4.73M | 4.61M | 2.05M | 2.06M | 1.72M | 1.42M | 1.48M | 2.23M | 2.17M | 2.37M | 2.20M | 1.30M | 300.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.31K | -14.35K | 634.54K | 547.16K | 300.00K | 300.00K | 100.00K |
| Operating Expenses | 3.40M | 657.93K | 325.40K | 1.06M | 2.75M | 4.56M | 5.12M | 7.02M | 3.95M | 3.94M | 1.88M | 560.67K | 982.10K | 1.03M | 3.08M | 4.73M | 4.61M | 2.05M | 2.06M | 1.72M | 1.42M | 1.48M | 2.23M | 2.95M | 3.30M | 3.00M | 2.20M | 700.00K |
| Cost & Expenses | 3.40M | 657.93K | 325.40K | 1.06M | 2.75M | 4.56M | 5.12M | 7.02M | 3.95M | 3.94M | 1.88M | 560.67K | 982.10K | 1.03M | 5.34M | 11.95M | 15.24M | 7.49M | 7.55M | 5.49M | 4.95M | 4.77M | 6.10M | 5.00M | 4.43M | 3.80M | 2.70M | 800.00K |
| Interest Income | 378.84K | 23.23 | 14.84 | 1.07K | 14.54K | 14.03K | 17.87K | 21.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.38K | 76.41K | 64.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 23.23K | 14.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.48K | 1.92K | 0.00 | 217.58K | 233.15K | 475.66K | 1.63M | 733.99K | 297.87K | 242.32K | 652.06K | 258.25K | 293.41K | 283.12K | 353.31K | 0.00 | 200.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 3.40M | 657.93K | 325.40K | 1.06M | 2.75M | 4.56M | 5.12M | 7.02M | 3.95K | 3.94K | 166.68K | 747.04K | 162.34K | 175.46K | 1.04M | 2.74M | 893.05K | 899.89K | 963.53K | 793.08K | 609.51K | 631.73K | 673.42K | 634.54K | 547.16K | 300.00K | 300.00K | 100.00K |
| EBITDA | 378.84K | -657.93K | -325.40K | -1.06M | -2.75M | 0.00 | 0.00 | 0.00 | -3.95M | -3.94M | -1.83M | 186.37K | -819.76K | -240.69K | -1.23M | -693.44K | -1.92M | -59.51K | 1.22M | 1.05M | 764.19K | 296.34K | -639.70K | 1.27K | -1.31M | -1.90M | -600.00K | 300.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14,865.30% | 0.00% | 0.00% | 0.00% | -39.44% | -24.62% | 49.25% | -16.27% | -2.51% | 14.71% | 17.95% | 14.52% | 6.68% | -10.46% | 0.03% | -51.25% | -137.50% | -33.33% | 30.00% |
| Operating Income | -3.40M | -657.93K | -325.40K | -1.06M | -2.75M | -4.56M | -5.12M | -7.02M | -3.95M | -3.94M | -2.00M | -560.67K | -982.10K | -416.16K | -2.07M | -2.52M | -2.81M | -959.40K | 253.04K | 261.55K | 154.68K | -340.70K | -1.33M | -633.27K | -1.86M | -2.20M | -900.00K | 200.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14,865.30% | 0.00% | 0.00% | 0.00% | -68.19% | -63.19% | -26.68% | -22.66% | -14.69% | 3.24% | 4.55% | 3.03% | -7.68% | -27.74% | -14.50% | -72.59% | -137.50% | -50.00% | 20.00% |
| Total Other Income/Expenses | 378.84K | 12.82M | 26.76K | 1.07K | 14.54K | 14.03K | 17.87K | 21.99K | 0.00 | -37.48K | 164.75K | 747.04K | 717.29K | -228.46K | -566.01K | -4.42M | 56.48K | 104.62K | -173.92K | -261.55K | -154.68K | -290.34K | -138.85K | -288.65K | -229.29K | 300.00K | -300.00K | -100.00K |
| Income Before Tax | -3.03M | 12.16M | -298.63K | -1.06M | -2.73M | -4.55M | -5.10M | -7.00M | -3.95M | -3.98M | -1.84M | 186.37K | -264.80K | -644.62K | -2.36M | -9.86M | -2.76M | -1.15M | 79.12K | -367.55K | -80.60K | -625.73K | -1.67M | -921.92K | -2.09M | -2.10M | -1.20M | 100.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 15,006.79% | 0.00% | 0.00% | 0.00% | -105.63% | -72.12% | -104.53% | -22.20% | -17.64% | 1.01% | -6.39% | -1.58% | -14.11% | -34.96% | -21.11% | -81.52% | -131.25% | -66.67% | 10.00% |
| Income Tax Expense | 0.00 | 55.11K | 14.84K | -1.07K | -14.54K | -14.03K | -17.87K | -21.99K | -3.95K | -3.94K | -166.68K | -747.04K | -36.91K | 359.65K | 2.36M | 9.86M | 2.76M | 1.15M | -79.12K | 367.55K | 80.60K | 625.73K | 1.67M | 921.92K | 2.09M | 2.10M | 1.20M | -100.00K |
| Net Income | -3.03M | 12.11M | -313.47K | -1.06M | -2.72M | -4.55M | -5.10M | -7.00M | -3.95M | -3.98M | -1.84M | 186.37K | -227.89K | -1.00M | -2.36M | -9.86M | -2.76M | -1.15M | 79.12K | -367.55K | -80.60K | -625.73K | -1.67M | -921.92K | -2.09M | -2.10M | -1.20M | 100.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 15,006.79% | 0.00% | 0.00% | 0.00% | -164.56% | -72.12% | -104.53% | -22.20% | -17.64% | 1.01% | -6.39% | -1.58% | -14.11% | -34.96% | -21.11% | -81.52% | -131.25% | -66.67% | 10.00% |
| EPS | -0.02 | 0.03 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 | -0.10 | 0.01 | -0.02 | -0.10 | -0.31 | -1.68 | -0.54 | -0.35 | 0.02 | -0.12 | -0.03 | -0.29 | -0.81 | -0.51 | -1.27 | -1.29 | -3.64 | 1.54 |
| EPS Diluted | -0.02 | 0.03 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 | -0.10 | 0.01 | -0.02 | -0.10 | -0.31 | -1.68 | -0.54 | -0.35 | 0.02 | -0.11 | -0.03 | -0.29 | -0.80 | -0.48 | -1.27 | -1.26 | -3.64 | 1.54 |
| Weighted Avg Shares Out | 151.31M | 366.18M | 376.25M | 371.93M | 370.43M | 369.81M | 366.62M | 288.75M | 232.62M | 95.88M | 17.94M | 13.65M | 12.11M | 9.86M | 7.55M | 5.86M | 5.13M | 3.29M | 3.96M | 3.06M | 2.69M | 2.16M | 2.07M | 1.81M | 1.65M | 1.63M | 329.48K | 1.59M |
| Weighted Avg Shares Out (Dil) | 171.95M | 367.78M | 376.25M | 371.93M | 370.43M | 369.81M | 366.62M | 288.75M | 232.62M | 95.88M | 17.94M | 13.65M | 12.11M | 9.86M | 7.55M | 5.86M | 5.13M | 3.29M | 3.96M | 3.34M | 2.69M | 2.16M | 2.08M | 1.92M | 1.65M | 1.67M | 329.48K | 1.59M |
Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight
The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). As medical research uncovers the...
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the treatment of Basal Cell Carcinomas in patients with Basal Cell Carcinoma Nevus Syndrome,...
3 Intriguing Stocks to Watch as Earnings Approach
As beneficiaries of strong business industries, Intuit (INTU), Workday (WDAY), and Booz Allen Hamilton's (BAH) stock all sport a Zacks Rank #2 (Buy) ahead of their quarterly reports this week.
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application ("NDA") to FDA TAMPA, Fla. , Dec. 19, 2023 /PRNewswire/ -- At the forefront of the Inhibitor...
Source: https://incomestatements.info
Category: Stock Reports